CLOs on the Move

X4 Pharmaceuticals

www.x4pharma.com

 
X4 Pharmaceuticals (Nasdaq: XFOR) is developing novel therapeutics designed to improve immune cell trafficking to treat rare diseases, including primary immunodeficiencies and certain cancers. The company`s oral small molecule drug candidates antagonize the CXCR4 pathway, which plays a central role in immune surveillance. X4`s most advanced product candidate, mavorixafor (X4P-001), is in a global Phase 3 pivotal trial in patients with WHIM syndrome, a rare, inherited, primary immunodeficiency disease, and is currently also under investigation in combination with axitinib in the Phase 2a portion of an open-label Phase 1/2 clinical trial in clear cell renal cell carcinoma (ccRCC). X4 is ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.x4pharma.com
  • 955 Massachusetts Avenue 4th Floor
    Cambridge, MA USA 02139
  • Phone: 857.529.8300

Executives

Name Title Contact Details
Natasha Thoren
Chief Legal and Compliance Officer Profile
Derek Meisner
General Counsel Profile

Similar Companies

Schmidt and Sons Pharmacy Inc

Schmidt & Sons Pharmacy Inc is a Tecumseh, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Terumo Blood and Cell Technologies

A global leader in blood management, blood safety, therapeutic apheresis, cell therapy and cell collections. Terumo BCT believes in the potential of blood to do even more for patients than it does today.

Harkness Pharmaceuticals

Harkness Pharmaceuticals, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

automation X

automation X is a Vienna, WV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Enanta

Enanta Pharmaceuticals is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections. Two protease inhibitors, glecaprevir and paritaprevir, discovered and developed through Enanta`s collaboration with AbbVie, have now been approved around the world as part of AbbVie`s regimens for the treatment of hepatitis C virus (HCV) infection. The leading regimen is sold under the tradenames MAVYRET™ (U.S.) and MAVIRET™ (ex-U.S.) (glecaprevir/pibrentasvir). Royalties from the AbbVie collaboration are helping to fund Enanta`s research and development efforts, which are currently focused on the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV), SARS-CoV-2 (COVID-19) and human metapneumovirus (hMPV).